Clinical observation on telbivudine and adefovir dipivoxil in the treatment of HBeAg positive chronic hepatitis B

OBJECTIVE To evaluate the efficacy and safety of 48 weeks telbivudine(LdT)treatment for chronic hepatitis B patients with HBeAg positive.METHODS 104 chronic hepatitis B patients with HBeAg positive were divided into treatment group(53 cases)and control group(51 cases).The treatment group was treated with telbivudine 600 mg per day orally for 48 weeks,the control group was treated with adefovir dipivoxil 10 mg per day orally for 48 weeks.The patients in both groups were observed of the rates of serum HBV-DNA clearance,ALT normalization,HBeAg loss,HBeAg seroconversion and side effects during the following 12,24,36 and 48 weeks.RESULTS After treatment of 12 weeks,24 weeks,36 weeks and 48 weeks,there were significant differences in the rates of serum HBV-DNA clearance and ALT normalization between the two groups(P﹤0.05),and there were no significant differences in the rates of HBeAg loss and HBeAg seroconversion(P﹥0.05).No severe adverse reactions were found in the treatment group.CONCLUSION Telbivudine is effective and safe in the treatment of chronic hepatitis B with HBeAg positive.